The scale of the BIOMAP consortium is unprecedented in the field of skin diseases. BIOMAP partners bring together biological samples, clinical information and ‘omics’ data from existing patient collections along with outstanding clinical and research expertise from diverse and complementary fields. Using this collaborative approach accompanied with data harmonization and standardized analysis strategies, BIOMAP pursues to answer open questions in the field using state-of-the-art methods in epidemiology, molecular profiling, skin biology and mathematical modelling to define new disease subpopulations (endotypes) and associated biomarkers.

BIOMAP findings will drive rapid drug discovery to target causal mechanisms. Biomarkers used alongside clinical signs will enable clinicians to know who, when and how to intervene, matching strategy (prevention, modification of risk factors, drug therapy) to particularly subgroups of AD and Pso (endotypes) to shift our current reactive, imprecise practice to pro-active strategies that encompass disease biology and life-time trajectory, with major benefit to people with AD and Pso.

BIOMAP is a major endeavour on the way to precision medicine in inflammatory skin disease.

Unmet needs in AD and Pso research

BIOMAP addresses three unmet needs in atopic dermatitis and psoriasis research which will have a broad impact on disease management, patient-directed care strategies and future trial designs:

  • The identification of major determinants of manifestation, progression and comorbidity development

  • An improved understanding of overlapping or unique disease mechanisms, associated signatures and their importance in patient subpopulations

  • The identification of markers capable of assessing disease-related individual patient trajectories and response to different therapies